Naturecell

At a glance

Naturecell filed 29 disclosures in the last 12 months, including 3 insider, 2 issuance and 1 m&a. The most recent key filing was on Oct 15: A ₩245B deal, equal to 327.2% of total assets.

Revenue for 2025 was ₩20.7B, down 35.9% on 2024. It made an operating loss of ₩3.6B. Debt was 19% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩10.3B and operating loss of ₩2B.

The 2025 annual report lists 83 employees with an average tenure of 7 years and average pay of ₩45.1M, #1647 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩66M each on average. It paid no cash dividend for 2025. (주)바이오스타줄기세포기술연구원 and related parties held 17.83% at year end.

From the 2025 annual report

Staff: 83 (47 men, 36 women), of whom 1 on fixed-term contracts. Total pay for the year: ₩3.7B. Directors and auditors: 9, paid ₩596M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)바이오스타줄기세포기술연구원 holds 9.24%; with 8 related parties the group holds 17.83% of common shares at year end (from 19.84% at the start of the year).

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary